VEGF and BDNF pathways play critical, interdependent roles in the antidepressant efficacy of ketamine in MDD as noted above, while in early-onset and late-onset AD, VEGF-A expression in the brain and vasculature undergoes complex, stage-dependent dysregulation (Ali et al., 2022). This evidence concerns the gene BDNF and major depressive disorder.